Composition for inhibiting dental plaque formation

Abstract

Provided is a means for suppressing the formation of dental plaque or the maturation of dental plaque on the surface of teeth. More specifically, provided is a composition for inhibiting the formation of dental plaque, which contains a quaternary ammonium salt having a C10-C14 alkyl group, and preferably further contains cetylpyridinium chloride.

Description

[0001] This application is a divisional application of an application with an application date of September 30, 2021, application number 202180067119.9, and invention name “Composition for inhibiting dental plaque formation”. Technical Field

[0002] The present disclosure relates to a composition for inhibiting the formation of dental plaque (tooth plaque), etc. It should be noted that the contents of all the documents described in this specification are incorporated into this specification by reference. Background Art

[0003] Dental plaque (tooth plaque) is a biofilm of microorganisms in the oral cavity, which is believed to be the cause of dental caries and periodontal disease. Therefore, it is important to control dental plaque, especially to inhibit the formation of dental plaque.

[0004] Generally speaking, dental plaque is formed as follows: First, a thin film of protein derived from saliva or physiological gingival sulcus fluid called "pellicle" is formed on the tooth surface, and facultative anaerobes such as streptococci (early adherent bacteria) adhere to the tooth surface through this pellicle. Mediating bacteria such as Fusobacterium that co-aggregate with various oral bacteria adhere to the early adherent bacteria, and late adherent bacteria such as Porphyromonas gingivalis and Treponema denticola, which are anaerobic bacteria, adhere and aggregate through the mediating bacteria, and dental plaque matures. It is known that late adherent bacteria in particular can cause periodontal disease and are directly or indirectly related to periodontal tissue damage.

[0005] Prior art literature

[0006] Non-patent literature

[0007] Non-patent document 1: J Dent Res 90(11):1271-1278, 2011 Summary of the invention

[0008] Problem that the invention aims to solve

[0009] In view of the above, in preventing periodontal disease, it is important to inhibit the formation of dental plaque on tooth surfaces, especially to inhibit the adhesion and aggregation of advanced adherent bacteria and the maturation of dental plaque.

[0010] Solutions for solving problems

[0011] The present inventors have focused on and conducted research on Fusobacterium, a mediating bacterium, because it is believed that if the action of Fusobacterium, a mediating bacterium that can coaggregate with various bacteria, can be inhibited, the adhesion and aggregation of late-adherent bacteria on the tooth surface can be inhibited, and even the maturation of dental plaque formation can be inhibited.

[0012] Therefore, research has been conducted on methods for sterilizing Fusobacterium, but despite attempts to study various bactericides commonly used in oral compositions, no bactericide has been found that can efficiently sterilize Fusobacterium.

[0013] As an example of a bactericide commonly used in oral compositions, cetylpyridinium chloride is no exception, and no efficient bactericidal effect is observed against Fusobacterium. However, after further research, the present inventors found that since cetylpyridinium chloride is a C16 alkylpyridinium chloride, there is a possibility that the length of the alkyl group has an effect on the bactericidal effect against Fusobacterium, and further improvements have been made.

[0014] The present disclosure includes, for example, the subject matters described in the following items.

[0015] Project 1.

[0016] A composition for inhibiting the formation of dental plaque, comprising: a quaternary ammonium salt having a C10-C14 alkyl group.

[0017] Project 2.

[0018] A composition for inhibiting the formation of dental plaque, comprising: a quaternary ammonium salt having a C10-C14 alkyl group and cetylpyridinium chloride.

[0019] Project 3.

[0020] The composition according to item 1 or 2, wherein the quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of a compound represented by formula (1) and a compound represented by formula (2):

[0021]

[0022] In formula (1), R represents a C10-C14 straight-chain alkyl group, and X represents Cl or Br;

[0023]

[0024] In formula (2), R 1 represents C10-C14 straight chain alkyl, R 2 and R 3 The same or different groups represent C1-C4 alkyl groups, and X represents Cl or Br.

[0025] Project 4.

[0026] The composition according to item 3, wherein the quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of a compound represented by formula (1a) and a compound represented by formula (2a):

[0027]

[0028] In formula (1a), R is the same as above;

[0029]

[0030] In formula (2a), R 1 Same as above.

[0031] Item 5.

[0032] A dental plaque formation inhibiting synergist of a quaternary ammonium salt having a C10-C14 alkyl group, comprising cetylpyridinium chloride.

[0033] Item 6.

[0034] The plaque formation inhibiting agent according to item 5, wherein the quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1) and compounds represented by formula (2):

[0035]

[0036] In formula (1), R represents a C10-C14 straight-chain alkyl group, and X represents Cl or Br;

[0037]

[0038] In formula (2), R 1 represents C10-C14 straight chain alkyl, R 2 and R 3 The same or different groups represent C1-C4 alkyl groups, and X represents Cl or Br.

[0039] Item 7.

[0040] The plaque formation inhibiting agent according to item 6, wherein the quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1a) and compounds represented by formula (2a):

[0041]

[0042] In formula (1a), R is the same as above;

[0043]

[0044] In formula (2a), R 1 Same as above.

[0045] Item 8.

[0046] A fusobacterium bactericidal synergist of a quaternary ammonium salt having a C10-C14 alkyl group, comprising cetylpyridinium chloride.

[0047] Item 9.

[0048] The fusobacterium bactericidal synergist according to item 8, wherein the quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1) and compounds represented by formula (2):

[0049]

[0050] In formula (1), R represents a C10-C14 straight-chain alkyl group, and X represents Cl or Br;

[0051]

[0052] In formula (2), R 1 represents C10-C14 straight chain alkyl, R 2 and R 3 The same or different groups represent C1-C4 alkyl groups, and X represents Cl or Br.

[0053] Item 10.

[0054] The fusobacterium bactericidal synergist according to item 9, wherein the quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1a) and compounds represented by formula (2a):

[0055]

[0056] In formula (1a), R is the same as above;

[0057]

[0058] In formula (2a), R 1 Same as above.

[0059] Effects of the Invention

[0060] A method for efficiently sterilizing Fusobacterium, which is a mediating bacterium in dental plaque formation, can be provided. Thus, dental plaque formation can also be efficiently inhibited. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 The results of a study on the bactericidal effect of quaternary ammonium salts (CPC and / or DPC) having a C10-C14 alkyl group on Fusobacterium are shown.

[0062] Figure 2The results of a study on the bactericidal effect of quaternary ammonium salts (CPC and / or OPC) having a C10-C14 alkyl group on Fusobacterium are shown.

[0063] Figure 3 The results of a study on the bactericidal effect of quaternary ammonium salts having a C10-C14 alkyl group (CPC and / or BKC12, BKC14 or BKC16) on fusobacteria are shown.

[0064] Figure 4a The results of a study on the bactericidal effect of alkylpyridinium chlorides (CPC and DPC) on Fusobacteria are shown.

[0065] Figure 4b The results of a study on the bactericidal effect of alkylpyridinium chlorides (CPC and OPC) on Fusobacteria are shown.

[0066] Figure 5 The results of a study on the bactericidal effect of compositions containing CPC and / or DPC on Fusobacterium are shown.

[0067] Figure 6 The results of a study on the bactericidal effect of compositions containing CPC and / or DPC on Fusobacterium are shown.

[0068] Figure 7a The results of a study on the bactericidal effect of alkylpyridinium chlorides (CPC and DPC) on Fusobacteria are shown.

[0069] Figure 7b The results of a study on the bactericidal effect of alkylpyridinium chlorides (CPC and DPC) on Fusobacteria are shown. DETAILED DESCRIPTION

[0070] The following further describes the various embodiments of the present disclosure in detail. The present disclosure preferably includes a composition for inhibiting dental plaque formation and a synergist for inhibiting dental plaque formation, but is not limited thereto, and the present disclosure includes all contents disclosed in this specification that can be understood by those skilled in the art.

[0071] The composition included in the present disclosure contains a quaternary ammonium salt having a C10-C14 (C10, C11, C12, C13 or C14) alkyl group, preferably further contains cetylpyridinium chloride. The composition is sometimes referred to as "the composition of the present disclosure". The composition of the present disclosure is preferably used to inhibit dental plaque formation, and when used for this purpose, it is sometimes specifically referred to as "the composition of the present disclosure for inhibiting dental plaque formation".

[0072] The quaternary ammonium salt having a C10-C14 alkyl group is preferably a chloride salt or a bromide salt. The alkyl group may be linear or branched, but is preferably linear.

[0073] More specifically, preferred examples of the quaternary ammonium salt having a C10-C14 alkyl group include a compound represented by formula (1) and a compound represented by formula (2).

[0074]

[0075] In formula (1), R represents a C10-C14 straight-chain alkyl group, and X represents Cl or Br;

[0076]

[0077] In formula (2), R 1 represents C10-C14 straight chain alkyl, R 2 and R 3 are identical or different and represent C1-C4 alkyl, and X represents Cl or Br. It should be noted that the C1-C4 alkyl here may be straight-chain or branched, preferably straight-chain. Although not particularly limited, methyl or ethyl is preferred, and R is particularly preferred. 2 and R 3 All are methyl groups. In addition, "C number" represents the number of carbon atoms. In addition, the compound represented by the formula (1) is sometimes referred to as "compound (1)", and the compound represented by the formula (2) is sometimes referred to as "compound (2)".

[0078] Among the compounds (1), more preferred are compounds represented by formula (1a);

[0079]

[0080] In formula (1a), R is the same as described above.

[0081] In addition, among the compounds (2), the compounds represented by formula (2a) are more preferred;

[0082]

[0083] In formula (2a), R 1 Same as above.

[0084] The quaternary ammonium salt having a C10-C14 alkyl group may be used alone or in combination of two or more.

[0085] The composition of the present disclosure can exhibit an excellent bactericidal effect against Fusobacteria by containing a quaternary ammonium salt having a C10-C14 (C10, C11, C12, C13 or C14) alkyl group, preferably further containing cetylpyridinium chloride, thereby being able to exhibit an excellent effect of inhibiting dental plaque formation.

[0086] Therefore, the composition of the present disclosure can also be preferably used as a composition for killing Fusobacteria.

[0087] The Fusobacterium herein is not particularly limited as long as it is a bacterium of the genus Fusobacterium that is a mediating bacterium of early-stage adhesion bacteria and late-stage adhesion bacteria in dental plaque formation, and a preferred example is Fusobacterium nucleatum.

[0088] When the composition of the present disclosure contains cetylpyridinium chloride, the content ratio of the quaternary ammonium salt having a C10-C14 alkyl group to cetylpyridinium chloride is, for example, preferably about 1 to 100 parts by mass of cetylpyridinium chloride relative to 10 parts by mass of the quaternary ammonium salt. The upper or lower limit of the range (1 to 100 parts by mass) may be, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 , 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 parts by mass. For example, the range may be about 2 to 90 parts by mass or about 5 to 50 parts by mass.

[0089] The content of the quaternary ammonium salt having a C10-C14 alkyl group in the composition of the present invention is not particularly limited as long as it is within a range that can exert the effect, and for example, it can be about 0.005 to 0.5 mass %. It should be noted that the upper limit or lower limit of the range can be, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.40, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.50, 0.51, 0.52, 0.53, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.60, 0.61, 0.62, 0.63, 0.64, 0.65 23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49 mass %. For example, the range may be about 0.01 to 0.3 mass %.

[0090] In addition, when the composition of the present invention contains cetylpyridinium chloride, the content of cetylpyridinium chloride is not particularly limited as long as it is within a range that can exert the effect, and for example, 0.01 to 0.5 mass % can be cited. It should be noted that the upper or lower limit of the range can be, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23 , 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49 mass %. For example, the range may be about 0.02 to 0.3 mass % or about 0.03 to 0.1 mass %.

[0091] As described above, although the inventors found that when cetylpyridinium chloride was used alone, no efficient bactericidal effect on Fusobacterium was observed, further research results showed that cetylpyridinium chloride had an enhanced bactericidal effect on Fusobacterium of quaternary ammonium salts having C10-C14 alkyl groups. Therefore, when the composition of the present disclosure contains cetylpyridinium chloride, it can exert a particularly excellent bactericidal effect on Fusobacterium and even exert an effect of inhibiting the formation of dental plaque.

[0092] Therefore, the present disclosure also includes: a fusobacterial bactericide comprising a quaternary ammonium salt having a C10-C14 alkyl group and cetylpyridinium chloride; and a synergist for inhibiting dental plaque formation comprising a quaternary ammonium salt having a C10-C14 alkyl group and cetylpyridinium chloride. The description of the composition of the present disclosure above involving cetylpyridinium chloride and a quaternary ammonium salt having a C10-C14 alkyl group is also preferably directly applicable to the description of the enhancer.

[0093] The composition of the present disclosure can be particularly preferably used as an oral composition. In addition, since the oral composition is useful for sterilizing Fusobacteria, it can also be preferably used for sterilizing Fusobacteria. That is, the composition of the present disclosure can be preferably used as an oral composition for inhibiting dental plaque formation or for sterilizing Fusobacteria. It should be noted that when the composition of the present disclosure is used as an oral composition, the composition is sometimes referred to as "the oral composition of the present disclosure".

[0094] The oral composition disclosed herein may be a solid composition or a liquid composition. The oral composition may be used as, for example, a medicine or a quasi-drug. In addition, the form of the oral composition disclosed herein is not particularly limited, and may be prepared in the form (dosage form) of, for example, an ointment, a paste, a paste, a gel, a liquid, a spray, a mouthwash, a liquid dentifrice, a toothpaste, a chewing gum, etc., according to conventional methods. Among them, preferably a mouthwash, a liquid dentifrice, a toothpaste, an ointment, a paste, a liquid, a gel.

[0095] The oral composition of the present disclosure may further contain one or more optional components that can be added to the oral composition within a range that does not impair the effects.

[0096] For example, as a surfactant, a nonionic surfactant, an anionic surfactant or an amphoteric surfactant may be added. Specifically, for example, as a nonionic surfactant, sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers having a polyoxyethylene addition coefficient of 8 to 10 and an alkyl carbon number of 13 to 15; polyoxyethylene alkylphenyl ethers having a polyoxyethylene addition coefficient of 10 to 18 and an alkyl carbon number of 9; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan, etc. As anionic surfactants, sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate can be listed; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; acylamino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methyl alanine; sodium cocoyl methyl taurine, etc. As zwitterionic surfactants, betaine-type acetic acid surfactants such as lauryl dimethylaminoacetic acid betaine and coconut oil fatty acid amide propyl dimethylaminoacetic acid betaine can be listed; imidazoline-type activators such as sodium N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine; amino acid-type activators such as N-lauryl diaminoethyl glycine, etc. These surfactants can be added alone or in combination of two or more. The amount added is usually 0.1 to 5% by mass relative to the total amount of the composition.

[0097] In addition, as flavoring agents, for example, menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronellal, α-terpineol, methyl acetate, citronellyl acetate, methyl eugenol, eucalyptol, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, allspice oil, right-handed camphor, right-handed borneol, anise oil, cinnamon oil, cinnamaldehyde, peppermint oil, vanillin and the like can be used. These can be added alone or in combination of two or more, and the amount thereof added is, for example, 0.001 to 1.5% by mass relative to the total amount of the composition.

[0098] In addition, as sweeteners, for example, saccharin sodium, acesulfame potassium, stevioside, neohesperidin dihydrochalcone, perilline, thaumatin, aspartame, p-methoxycinnamaldehyde, etc. can be used, for example, in an amount of 0.01 to 1% by mass based on the total amount of the composition.

[0099] Furthermore, as moisturizers, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, etc. may be added. These may be added alone or in combination of two or more.

[0100] As the preservative, parabens such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben; sodium benzoate, phenoxyethanol, alkyl diaminoethyl glycine hydrochloride, etc. can be added.

[0101] As coloring agents, legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3; mineral pigments such as Ultramarine, Enhanced Ultramarine, and Prussian Blue; titanium oxide, etc. may be added.

[0102] As a pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid or a chemically possible salt thereof, sodium hydroxide, etc. can be added. These can be added alone or in combination of two or more to adjust the pH of the composition to a range of 4 to 8, preferably 5 to 7. The amount of the pH adjuster added can be, for example, 0.01 to 2% by weight.

[0103] The oral composition disclosed herein may be formulated with, in addition to the quaternary ammonium salt of a C10-C14 alkyl group and cetylpyridinium chloride, vitamin E such as dl-α-tocopheryl acetate, tocopheryl succinate or tocopheryl nicotinate as an effective ingredient; amphoteric bactericides such as dodecyldiaminoethylglycine; nonionic bactericides such as triclosan, isopropylmethylphenol, and cypress phenol; anionic bactericides such as sodium lauroylsarcosinate; cationic bactericides such as chlorhexidine gluconate and benzethonium chloride; dextranase, amylase, protease, mutans, lysozyme, lytic enzymes, etc. enzyme); alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate; fluorides such as sodium fluoride and stannous fluoride; tranexamic acid, ε-aminocaproic acid, aluminum chlorohydroxyallantoin, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizic acid, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, seal peptide, allantoin, carbaclot, cypress phenol, potassium nitrate, isomalt, etc., which can be added alone or in combination of two or more.

[0104] In addition, as a base, alcohols, silicon, apatite, white vaseline, paraffin, liquid paraffin, microcrystalline wax, squalane, plastic bases, etc. can be added.

[0105] The oral composition of the present disclosure can be prepared by a known method or a method easily conceivable from a known method, for example, by appropriately mixing a quaternary ammonium salt having a C10-C14 alkyl group, preferably cetylpyridinium chloride, and other components added as needed.

[0106] The objects to which the oral composition of the present invention is applicable are not particularly limited, and preferably humans and non-human mammals. As non-human mammals, livestock and pets are preferred, and more specifically, dogs, cats, mice, rats, horses, cows, sheep, monkeys, etc. can be listed. In addition, since the oral composition of the present invention contains a quaternary ammonium salt having a C10-C14 alkyl group as described above, and preferably further contains cetylpyridinium chloride, it can efficiently sterilize Fusobacterium, which is a mediating bacteria, and it can be said that it is particularly suitable for use in the oral cavity of an object where dental plaque has not yet formed or is forming dental plaque (late-stage adhesion bacteria are not adhered).

[0107] In addition, the above description about the oral composition of the present disclosure is also applicable to the composition of the present disclosure that is not used as an oral composition (for example, the case of using it for denture cleaning).

[0108] The term "comprising" in this specification also encompasses "consisting essentially of" and "consisting of." In addition, the present disclosure includes all arbitrary combinations of the technical features described in this specification.

[0109] In addition, the various characteristics (properties, structures, functions, etc.) described above for each embodiment of the present disclosure can be arbitrarily combined when used to limit the subject matter included in the present disclosure. That is, the present disclosure includes all the subject matters constituted by all combinations of the combinable characteristics recorded in this specification.

[0110] Example

[0111] The following examples are used to more specifically describe the embodiments of the present disclosure, but the embodiments of the present disclosure are not limited to the following examples.

[0112] Study on the bactericidal effect of quaternary ammonium salts on Fusobacterium

[0113] The following alkylpyridinium chloride and benzylalkyldimethylammonium chloride are dissolved in water in such a manner that each component reaches a concentration (0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.07% or 0.10%), and used as a disinfectant liquid. In the disinfectant liquid, the components are used alone or in combination. It should be noted that the alkylpyridinium chloride concentration (%) of the disinfectant liquid is w / v%, but since the solvent is water and the concentration is relatively low, this value is almost the same as the mass % (w / w%) and can be approximately calculated.

[0114] Octylpyridinium chloride (OPC): R = (CH2)7CH3

[0115] Dodecylpyridinium chloride (DPC): R = (CH2) 11 CH3

[0116] Hexadecylpyridinium chloride (CPC): R = (CH2) 15 CH3

[0117]

[0118] Benzyldodecyldimethylammonium chloride (BKC12):

[0119] In the following formula, R 1 =C 12 H 25

[0120] Benzyltetradecyldimethylammonium chloride (BKC14):

[0121] In the following formula, R 1 =C 14 H 29

[0122] Benzylhexadecyldimethylammonium chloride (BKC16):

[0123] In the following formula, R 1 =C 16 H 33

[0124]

[0125] In addition, the following two subspecies of Fusobacterium were used as test bacteria.

[0126] Bacteria 1: Fusobacterium nucleatum subsp. nucleatum ATCC23726

[0127] Bacteria 2: Fusobacterium nucleatum subsp. nucleatum ATCC25586

[0128] The test bacteria were inoculated into 10 ml of GAM broth medium (Nissui Pharmaceutical Co., Ltd.), and cultured anaerobically at 37° C. for 2 days. This culture solution was used as the test bacterial solution.

[0129] 200 μl of the test bacterial solution was mixed with 200 μl of the fungicide solution of different concentrations. After mixing for 30 seconds, 100 μl of the mixture was collected and 900 μl of the drug-inactivated PBS prepared by adding soybean lecithin and Tween 80 to phosphate buffered saline (PBS) at a final concentration of 0.07% and 0.5%, respectively, was added thereto (the mixture was diluted 10 times) to inactivate the fungicide. In addition, the mixture was diluted stepwise with the drug-inactivated PBS until the mixture was diluted to 10 1 ~10 7 times (stage mixture dilution).

[0130] 100 μl of each of the prepared step mixed solution dilutions was spread on CDC sheep blood agar medium for anaerobic bacteria (Becton Dickinson Japan Co., Ltd.), anaerobically cultured at 37°C for 3 days, and the number of viable bacteria was counted.

[0131] The results are shown in Figure 1 , Figure 2 and Figure 3It should be noted that these graphs are graphs with Log (viable count) CFU / ml as the vertical axis, and the detection limit of this value is 2 (a value less than 2 indicates sterilization to less than 100 CFU). In addition, the concentrations of CPC, DPC, OPC, BKC12, BKC14, and BKC16 in these graphs and the following graphs represent the concentrations of the components in the prepared disinfectant solution.

[0132] It can be seen that CPC and OPC did not show bactericidal effect on Fusobacterium, while DPC showed bactericidal effect on Fusobacterium even at a lower concentration. In addition, it can be seen that although CPC alone did not show bactericidal effect on Fusobacterium, when combined with DPC, the bactericidal effect of DPC on Fusobacterium was enhanced.

[0133] Here, the results of using OPC, DPC or CPC separately are divided into Figure 1 and Figure 2 Extracted from the Figure 4a and Figure 4b .

[0134] In addition, it can be seen that BKC16 did not show a bactericidal effect on Fusobacterium, while BKC14 or BKC12 showed a bactericidal effect on Fusobacterium even at a lower concentration. In addition, it can be seen that although CPC alone did not show a bactericidal effect on Fusobacterium, when combined with BKC14 or BKC12, the bactericidal effect of BKC14 or BKC12 on Fusobacterium was enhanced.

[0135] Study on the bactericidal effect of a composition containing quaternary ammonium salt and CPC on Fusobacterium

[0136] In addition to the quaternary ammonium salt and CPC, a fragrance, a preservative, a solubilizer (polyoxyethylene hydrogenated castor oil), etc. were mixed in water and a solvent (glycerin) to prepare a liquid composition containing the quaternary ammonium salt and CPC at various concentrations.

[0137] The same operation as above was carried out using this liquid composition to examine the bactericidal effect. The results are shown in Figure 5 .

[0138] In addition, the liquid composition was subjected to the same operation as above to examine the bactericidal effect on more Fusobacterium subspecies. That is, the following bacteria 3, bacteria 4, bacteria 5, bacteria 6 and bacteria 7 were used instead of bacteria 1 and 2 to examine the bactericidal effect. The results are shown in Figure 6 .

[0139] Bacteria 3: Fusobacterium necrophorum subsp. necrophorum ATCC25286

[0140] Bacteria 4: Fusobacterium nucleatum subsp. polymorphum ATCC10953

[0141] Bacteria 5: Fusobacterium nucleatum subsp. Fusiforme ATCC51190

[0142] Bacteria 6: Fusobacterium nucleatum subsp.vincentii ATCC49256

[0143] Bacteria 7: Fusobacterium nucleatum subsp.animalis ATCC51191

[0144] It could be confirmed that the studied compositions containing DPC and CPC sterilized Fusobacterium to below the detection limit.

[0145] In addition, similarly to the above, the bactericidal effects of compositions containing alkylpyridinium chlorides at various concentrations alone or in combination against Fusobacterium were also examined again. The results are shown in Figure 7a and Figure 7b .

[0146] The following are examples of compounding ratios. It should be noted that the values ​​of each component in the following examples of compounding ratios are expressed in mass %.

[0147] Recipe Example

[0148] [Liquid Gel]

[0149] [Table 1]

[0150] Recipe Example 1 2 3 4 5 6 7 8 9 10 11 12 Sodium lauryl sulfate 0.4 0.2 0.1 Sodium olefin (C14-16) sulfonate 0.1 Sodium N-myristoyl-L-glutamate 0.1 Sodium lauroyl sarcosinate 0.1 Polyethylene glycol myristate (15.E.0) 0.1 Propylene glycol alginate 0.1 Polyoxyethylene hydrogenated castor oil (60.E.0) 0.3 0.5 0.5 0.3 1.5 1 0.5 0.4 0.2 Sucrose Stearate 0.05 Isodecyl galactoside 0.08 Concentrated glycerin 10 18 3 15 2 10 10 10 10 5 Sorbitol 20 35 Erythritol 5 15 Xylitol 4 1 1 Reduced Palatinose 3 1 Propylene glycol 5 8 2 2 0.5 5 5 5 Ethanol 10 8 4 2 10 5 6 Carrageenan 0.05 Hexadecylpyridinium chloride 0.05 0.03 0.05 0.05 0.03 0.05 0.05 0.05 0.05 0.05 0.07 0.07 Benzalkonium chloride 0.05 0.01 0.03 0.03 0.03 0.03 0.03 0.01 0.01 0.03 Amyl ammonium chloride 0.01 Dodecylpyridinium chloride 0.01 0.05 0.05 0.01 0.05 0.05 0.05 0.05 0.05 0.01 0.05 Isopropyl methylphenol 0.1 0.01 0.05 Allantoin Aluminum Chlorohydroxy 0.1 Dipotassium glycyrrhizinate 0.03 0.02 Tocopheryl acetate 0.05 Urea 0.05 Sodium fluoride 0.1 β-Glycyrrhetinic acid 0.03 Tranexamic acid 0.05 Citric Acid 0.01 0.01 0.05 0.01 0.01 0.03 0.01 Sodium Citrate 0.3 Trisodium Citrate 0.1 0.1 0.1 0.1 0.1 0.1 Sodium dihydrogen phosphate 0.1 Sodium Hydrogen Phosphate 0.01 Sodium hydroxide 0.07 0.1 Alanine 0.5 Sucralose 0.001 0.006 0.03 Saccharin Sodium 0.01 0.3 0.01 0.01 0.01 0.02 Stevioside 0.1 0.005 Acesulfame Potassium 0.01 0.03 Fragrance composition 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0..1 0.2 Purified water margin margin margin margin margin margin margin margin margin margin margin margin total 100 100 100 100 100 100 100 100 100 100 100 100

[0151] [Toothpaste][Table 2]

[0152] Recipe Example 13 14 15 16 17 18 19 Abrasive Silica 20 15 13 12 8 Thickening Silica 5 10 2 4 Calcium Hydrogen Phosphate for Toothpaste 25 5 Anhydrous calcium hydrogen phosphate 5 10 10 Calcium carbonate 20 Sodium Carboxymethyl Cellulose 0.3 1 1.5 1 1 Sodium lauroyl sarcosinate 0.1 Xanthan gum 1.5 0.2 Carrageenan 0.5 0.2 Cellulose particles 5 Sodium alginate 0.3 Concentrated glycerin 10 5 20 Propylene glycol 5 3 Polyethylene glycol 400 5 Polyethylene glycol 600 1 Sorbitol 20 25 20 20 25 Xylitol 0.1 10 Erythritol 35 Sodium lauryl sulfate 3.5 1 1.5 2.5 Methyl Lauroyl Taurine 0.3 Coconut Oil Fatty Acid Amidopropyl Betaine 1 Polyoxyethylene (60) hydrogenated castor oil 1 2 0.5 Sodium fluoride 0.2 0.3 0.2 Sodium monofluorophosphate 1.1 0.7 Hexadecylpyridinium chloride 0.05 0.05 0.05 0.1 0.05 0.05 0.05 Benzalkonium chloride 0.03 0.03 0.03 0.01 0.05 0.03 0.01 Benzethonium chloride 0.01 Dodecylpyridinium chloride 0.1 0.2 0.05 0.03 0.4 0.2 Isopropyl methylphenol 0.03 0.1 0.05 Dipotassium glycyrrhizinate 0.02 β-Glycyrrhetinic acid 0.1 Tocopheryl acetate 0.05 Allantoin 0.05 Tranexamic acid 0.05 Pyrrolidone carboxylic acid 5 3 5 Phytic Acid 0.3 DL-Malic Acid 0.1 Sodium tripolyphosphate 0.5 Sodium hydroxide 0.1 Titanium oxide 0.5 0.8 0.2 0.3 Saccharin Sodium 0.3 0.05 0.1 0.05 0.1 Aspartame 0.02 0.03 Acesulfame Potassium 0.05 0.01 0.02 Fragrance composition 1 1 1 1 1 1 1 Purified water margin margin margin margin margin margin margin total 100 100 100 100 100 100 100

Claims

1. Use of cetylpyridinium chloride in the manufacture of a quaternary ammonium salt having a C10-C14 alkyl group for inhibiting the formation of dental plaque, wherein the dental plaque is formed by Fusobacterium.

2. The use according to claim 1, wherein: The quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1) and compounds represented by formula (2): In formula (1), R represents a C10-C14 straight-chain alkyl group, and X represents Cl or Br; In formula (2), R 1 represents C10-C14 straight chain alkyl, R 2 and R 3 The same or different groups represent C1-C4 alkyl groups, and X represents Cl or Br.

3. The use according to claim 2, wherein: The quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1a) and compounds represented by formula (2a): In formula (1a), R is the same as above; In formula (2a), R 1 Same as above.

4. Application of hexadecylpyridinium chloride in the manufacture of a fusobacterial bactericidal enhancer of a quaternary ammonium salt having a C10-C14 alkyl group.

5. The use according to claim 4, wherein: The quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1) and compounds represented by formula (2): In formula (1), R represents a C10-C14 straight-chain alkyl group, and X represents Cl or Br; In formula (2), R 1 represents C10-C14 straight chain alkyl, R 2 and R 3 The same or different groups represent C1-C4 alkyl groups, and X represents Cl or Br.

6. The use according to claim 5, wherein: The quaternary ammonium salt having a C10-C14 alkyl group is at least one selected from the group consisting of compounds represented by formula (1a) and compounds represented by formula (2a): In formula (1a), R is the same as above; In formula (2a), R 1 Same as above.

7. Use of dodecylpyridinium chloride in the manufacture of a composition for inhibiting the formation of dental plaque, wherein the dental plaque is formed by Fusobacterium.

8. Use of dodecylpyridinium chloride in the manufacture of a composition for killing fusobacteria.

9. Use of hexadecylpyridinium chloride in the manufacture of a synergist of dodecylpyridinium chloride for inhibiting the formation of dental plaque, wherein the dental plaque is formed by Fusobacterium.

10. Application of hexadecylpyridinium chloride in the manufacture of dodecylpyridinium chloride as a fusobacterial bactericidal enhancer.

Images